



February 15, 2017

Aerie Pharmaceuticals to Present at the RBC Capital Markets 2017 Global Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer, will present in a fireside chat discussion at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22, 2017 at 8:30 a.m. Eastern Time in New York, NY. Dr. Kopczynski will provide his perspective on Aerie's lead product candidates, as well as ongoing pre-clinical activities.

The fireside chat discussion will be webcast live and may be accessed by visiting Aerie's website at <http://investors.aeriepharma.com/>. A replay of the webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA filing for RhopressaTM (netarsudil ophthalmic solution) 0.02% was originally submitted in the third quarter of 2016 and is expected to be resubmitted near the end of the first quarter of 2017. The second product candidate, RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of RhopressaTM and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a RoclatanTM NDA filing is expected to take place near year-end 2017. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20170215005009/en/): <http://www.businesswire.com/news/home/20170215005009/en/>

Aerie Pharmaceuticals
Richard Rubino, 908-947-3540
rrubino@aeriepharma.com

or
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com

Source: Aerie Pharmaceuticals, Inc.

News Provided by Acquire Media